

---

**From:** [REDACTED]  
**Sent:** Friday, 27 November 2020 8:30 AM  
**To:** Bell, Simon; Channing, Darrell  
**Cc:** Exemptions; [REDACTED]  
**Subject:** Medicines Australia – ACCC Authorisation AA1000486 – fortnightly report 14 November 2020 – 27 November 2020 – NIL report

Dear Simon/Darell,

In relation to the ACCC Authorisation **AA1000486** (24 September 2020) and, specifically, in accordance with the Conditions of that Authorisation at paragraph 5.12, Medicines Australia provides the following fortnightly report on activities related to the Proposed Conduct.

In the period of 14 November 2020 to 27 November 2020, no meetings or discussions of the Medicines Australia/Generic and Biosimilar Medicines Association Working Group occurred and no decisions were made that fall under the Proposed Conduct.

Medicines Australia's next fortnightly update will cover the period of 28 November 2020 to 11 December 2020. Additional updates will be provided to the ACCC as required and in accordance with Medicines Australia's obligations under the authorisation.

We also consent to this email being published on the public register, with the appropriate privacy redactions.

This response was drafted in consultation with [REDACTED], CEO of Generic and Biosimilar Medicines Association.

Yours sincerely,

[REDACTED]

[REDACTED]  
Manager, Industry and Regulatory Policy  
Medicines Australia

***\*Please note that due to COVID-19, Medicines Australia's staff are now working from home. Revised contact details below. If your matter is urgent, please call my mobile in addition to emailing to ensure a prompt response.***

17 Denison Street  
Deakin ACT 2600  
Australia

Main Office: +61 2 6147 6500

Mobile: [REDACTED]

Email: [REDACTED]

Web: [www.medicinesaustralia.com.au](http://www.medicinesaustralia.com.au)





 Please consider the environment before printing this email message